A new target for an old drug: Identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2619-2629

  Wan, Xiaobo ^a,b   Zhang, Wei ^b   Li, Li ^b   Xie, Yuting ^b   Li, Wei ^a,b   Huang, Niu ^a,b  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; A 674563; CRIZOTINIB; DASATINIB; DNA TOPOISOMERASE (ATP HYDROLYSING); ERLOTINIB; FLAVOPIRIDOL; FOSTAMATINIB; GEFITINIB; MITOXANTRONE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE PIM 1; RUBOXISTAURIN; SGI 1776; STAUROSPORINE; SUNITINIB; TAE 684; TOFACITINIB; TOZASERTIB; UNCLASSIFIED DRUG; VANDETANIB;

ARTICLE; CANCER CELL; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DNA BINDING; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; INTERCALATION COMPLEX; PHYSICS; RETROSPECTIVE STUDY;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG APPROVAL; GENOMICS; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; MITOXANTRONE; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84875732199     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400045y     Document Type: Article

References (71)

1. Thaimattam, R.; Banerjee, R.; Miglani, R.; Iqbal, J. Protein Kinase Inhibitors: Structural Insights Into Selectivity Curr. Pharm. Des. 2007, 13, 2751-2765
2. Morphy, R. Selectively Nonselective Kinase Inhibition: Striking the Right Balance J. Med. Chem. 2009, 53, 1413-1437
3. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 2004, 64, 7099-7109
4. Lin, X.; Huang, X.-P.; Chen, G.; Whaley, R.; Peng, S.; Wang, Y.; Zhang, G.; Wang, S. X.; Wang, S.; Roth, B. L.; Huang, N. Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors J. Med. Chem. 2012, 55, 5749-5759
5. Sheinerman, F. B.; Giraud, E.; Laoui, A. High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding J. Mol. Biol. 2005, 352, 1134-1156
6. Subramanian, G.; Sud, M. Computational Modeling of Kinase Inhibitor Selectivity ACS Med. Chem. Lett. 2010, 1, 395-399
7. Brylinski, M.; Skolnick, J. Comprehensive Structural and Functional Characterization of the Human Kinome by Protein Structure Modeling and Ligand Virtual Screening J. Chem. Inf. Model. 2010, 50, 1839-1854
8. KIN: A Chemical Systems Biology Approach Mol. Pharmaceutics 2010, 7, 2324-2333
9. Rockey, W. M.; Elcock, A. H. Rapid computational identification of the targets of protein kinase inhibitors J. Med. Chem. 2005, 48, 4138-4152
10. Martin, L.; Catherinot, V.; Labesse, G. kinDOCK: a tool for comparative docking of protein kinase ligands Nucleic Acids Res. 2006, 34, W325-W329
11. Huang, N.; Kalyanaraman, C.; Bernacki, K.; Jacobson, M. P. Molecular mechanics methods for predicting protein-ligand binding Phys. Chem. Chem. Phys. 2006, 8, 5166-5177
12. Huang, N.; Jacobson, M. P. Physics-based methods for studying protein-ligand interactions Curr. Opin. Drug Discovery Dev. 2007, 10, 325-331
13. Kalyanaraman, C.; Bernacki, K.; Jacobson, M. P. Virtual Screening against Highly Charged Active Sites: Identifying Substrates of Alpha-Beta Barrel Enzymes Biochemistry 2005, 44, 2059-2071
14. Huang, N.; Kalyanaraman, C.; Irwin, J. J.; Jacobson, M. P. Physics-based scoring of protein-ligand complexes: enrichment of known inhibitors in large-scale virtual screening J. Chem. Inf. Model. 2006, 46, 243-253
15. Peng, S.; Lin, X.; Guo, Z.; Huang, N. Identifying Multiple-target Ligands via Computational Chemogenomics Approaches Curr. Trends Med. Chem. 2012, 12, 1363-1375
16. Fry, D. W. Biochemical pharmacology of anthracenediones and anthrapyrazoles Pharmacol. Ther. 1991, 52, 109-125
17. Capranico, G.; De Isabella, P.; Tinelli, S.; Bigioni, M.; Zunino, F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II Biochemistry 1993, 32, 3038-3046
18. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
19. Pearlman, D. A.; Charifson, P. S. Are Free Energy Calculations Useful in Practice? A Comparison with Rapid Scoring Functions for the p38 MAP Kinase Protein System J. Med. Chem. 2001, 44, 3417-3423
20. Kufareva, I.; Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states J. Med. Chem. 2008, 51, 7921-7932
21. Jacobs, M. D.; Caron, P. R.; Hare, B. J. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex Proteins 2008, 70, 1451-1460
22. Brooijmans, N.; Chang, Y. W.; Mobilio, D.; Denny, R. A.; Humblet, C. An enriched structural kinase database to enable kinome-wide structure-based analyses and drug discovery Protein Sci. 2010, 19, 763-774
23. Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M. J.; He, Y. A.; Jacques, S. L.; Lunney, E. A.; McTigue, M.; Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H. M.; Demetri, G. D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1542-1547
24. Kutach, A. K.; Villaseñor, A. G.; Lam, D.; Belunis, C.; Janson, C.; Lok, S.; Hong, L.-N.; Liu, C.-M.; Deval, J.; Novak, T. J.; Barnett, J. W.; Chu, W.; Shaw, D.; Kuglstatter, A. Crystal Structures of IL-2-inducible T cell Kinase Complexed with Inhibitors: Insights into Rational Drug Design and Activity Regulation Chem. Biol. Drug Des. 2010, 76, 154-163
25. Vogtherr, M.; Saxena, K.; Hoelder, S.; Grimme, S.; Betz, M.; Schieborr, U.; Pescatore, B.; Robin, M.; Delarbre, L.; Langer, T.; Wendt, K. U.; Schwalbe, H. NMR characterization of kinase p38 dynamics in free and ligand-bound forms Angew. Chem., Int. Ed. 2006, 45, 993-997
26. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: a practical alternative Curr. Opin. Struct. Biol. 2008, 18, 178-184
27. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase Science 2000, 289, 1938-1942
28. Powles, T. J. Evolving clinical strategies: innovative approaches to the use of mitoxantrone-introduction Eur. J. Cancer Care 2008, 6, 1-3
29. Harris, K. A.; Reese, D. M. Treatment options in hormone-refractory prostate cancer: current and future approaches Drugs 2001, 61, 2177-2192
30. Rigacci, L.; Carpaneto, A.; Alterini, R.; Carrai, V.; Bernardi, F.; Bellesi, G.; Longo, G.; Bosi, A.; Rossi Ferrini, P. Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results Cancer 2003, 97, 97-104
31. Bhalla, K.; Ibrado, A. M.; Tourkina, E.; Tang, C.; Grant, S.; Bullock, G.; Huang, Y.; Ponnathpur, V.; Mahoney, M. E. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells Blood 1993, 82, 3133-3140
32. Bellosillo, B.; Colomer, D.; Pons, G.; Gil, J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells Br. J. Hamaetol. 1998, 100, 142-146
33. Parker, C.; Waters, R.; Leighton, C.; Hancock, J.; Sutton, R.; Moorman, A. V.; Ancliff, P.; Morgan, M.; Masurekar, A.; Goulden, N.; Green, N.; Révész, T.; Darbyshire, P.; Love, S.; Saha, V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial Lancet 2010, 376, 2009-2017
34. Coufal, N.; Farnaes, L. Anthracyclines and Anthracenediones. In Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures; Minev, B. R., Ed.; Springer: The Netherlands, 2011; Vol. 13, pp 87-102.
35. Wehenkel, A.; Fernandez, P.; Bellinzoni, M.; Catherinot, V.; Barilone, N.; Labesse, G.; Jackson, M.; Alzari, P. M. The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria FEBS Lett. 2006, 580, 3018-3022
36. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1039-1045
37. Li, C. M.; Liu, X. G.; Lin, X. C.; Chen, X. W.; Liang, N. C. Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme Aizheng 2008, 27, 809-815
38. Kumar, A.; Mandiyan, V.; Suzuki, Y.; Zhang, C.; Rice, J.; Tsai, J.; Artis, D. R.; Ibrahim, P.; Bremer, R. Crystal Structures of Proto-oncogene Kinase Pim1: A Target of Aberrant Somatic Hypermutations in Diffuse Large Cell Lymphoma J. Mol. Biol. 2005, 348, 183-193
39. Zheng, S.; Chen, Y.; Donahue, C. P.; Wolfe, M. S.; Varani, G. Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone) Chem. Biol. 2009, 16, 557-566
40. Bullock, A. N.; Debreczeni, J.; Amos, A. L.; Knapp, S.; Turk, B. E. Structure and substrate specificity of the Pim-1 kinase J. Biol. Chem. 2005, 280, 41675-41682
41. Peng, C.; Knebel, A.; Morrice, N. A.; Li, X.; Barringer, K.; Li, J.; Jakes, S.; Werneburg, B.; Wang, L. Pim kinase substrate identification and specificity J. Biochem. 2007, 141, 353-362
42. Aho, T. L.; Sandholm, J.; Peltola, K. J.; Mankonen, H. P.; Lilly, M.; Koskinen, P. J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site FEBS Lett. 2004, 571, 43-49
43. Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural Analysis Identifies Imidazo[1,2-b]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity Cancer Res. 2007, 67, 6916-6924
44. Amson, R.; Sigaux, F.; Przedborski, S.; Flandrin, G.; Givol, D.; Telerman, A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8857-8861
45. Cibull, T. L.; Jones, T. D.; Li, L.; Eble, J. N.; Ann Baldridge, L.; Malott, S. R.; Luo, Y.; Cheng, L. Overexpression of Pim-1 during progression of prostatic adenocarcinoma J. Clin. Pathol. 2006, 59, 285-288
46. Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150-4157
47. Nawijn, M. C.; Alendar, A.; Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis Nat. Rev. Cancer 2011, 11, 23-34
48. Chen, L. S.; Redkar, S.; Taverna, P.; Cortes, J. E.; Gandhi, V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia Blood 2011, 118, 693-702
49. Fathi, A. T.; Arowojolu, O.; Swinnen, I.; Sato, T.; Rajkhowa, T.; Small, D.; Marmsater, F.; Robinson, J. E.; Gross, S. D.; Martinson, M.; Allen, S.; Kallan, N. C.; Levis, M. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase Leuk. Res. 2012, 36, 224-231
50. Sundman-Engberg, B.; Tidefelt, U.; Gruber, A.; Paul, C. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo Leuk. Res. 1993, 17, 347-352
51. Robinson, J.; Pheneger, J.; Patrice, L.; Wright, D.; Brown, S.; Sullivan, F.; Davis, A. G. A Dual PIM 1/3 Kinase Inhibitor Demonstrates Efficacy in Murine Models of Lupus and Multiple Sclerosis J. Immunol. 2012, 188, 199.9
52. Raju, T. N. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98) Lancet 2000, 355, 1022
53. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J. Basic local alignment search tool J. Mol. Biol. 1990, 215, 403-410
54. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases Cell 2002, 109, 275-282
55. Kelley, L. A.; Gardner, S. P.; Sutcliffe, M. J. An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies Protein Eng. 1996, 9, 1063-1065
56. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
57. Jacobson, M. P.; Kaminski, G. A.; Friesner, R. A.; Rapp, C. S. Force field validation using protein side chain prediction J. Phys. Chem. 2002, 106, 11673-11680
58. Zhu, K.; Shirts, M. R.; Friesner, R. A. Improved Methods for Side Chain and Loop Predictions via the Protein Local Optimization Program:Variable Dielectric Model for Implicitly Improving the Treatment of Polarization Effects J. Chem. Theory Comput. 2007, 3, 2108-2119
59. Huang, N.; Jacobson, M. P. Binding-site assessment by virtual fragment screening. PLoS One 5, e10109.
60. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking J. Med. Chem. 2006, 49, 6789-6801
61. Case, D. A.; Cheatham, T. E., 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26, 1668-1688
62. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
63. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
64. Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method J. Comput. Chem. 2000, 21, 132-146
65. Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation J. Comput. Chem. 2002, 23, 1623-1641
66. Luo, R.; David, L.; Gilson, M. K. Accelerated Poisson-Boltzmann calculations for static and dynamic systems J. Comput. Chem. 2002, 23, 1244-1253
67. Sitkoff, D.; Sharp, K. A.; Honig, B. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models J. Phys. Chem. 1994, 98, 1978-1988
68. Erijman, A.; Dantes, A.; Bernheim, R.; Shifman, J. M.; Peleg, Y. Transfer-PCR (TPCR): a highway for DNA cloning and protein engineering J. Struct. Biol. 2011, 175, 171-177
69. Qian, K. C.; Studts, J.; Wang, L.; Barringer, K.; Kronkaitis, A.; Peng, C.; Baptiste, A.; LaFrance, R.; Mische, S.; Farmer, B. Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2005, 61, 96-99
70. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
71. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, USA, 2002; computer program.